Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymes™ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATOR™, FabALACTICA™, GingisKHAN™, FabULOUS™ & FabRICATOR Z™ General proteolysis - GingisREX™ De-glycosylation and conjugation of IgGs - GlycINATOR™, IgGZERO™ and GlyCLICK™ O-glycan analysis - OglyZOR™, OpeRATOR™, GlycOCATCH™ and SialEXO™
Looking for a particular Genovis employee's phone or email?
Genovis Questions
The Genovis annual revenue was $14.8 million in 2026.
Fredrik Olsson is the CEO of Genovis.
36 people are employed at Genovis.
The NAICS codes for Genovis are [54171, 541713, 5417, 54, 541].
The SIC codes for Genovis are [87, 873].
Top Genovis Employees
-
Fredrik Olsson
CEO at Genovis
Lund, SE12 -
3
-
Stephan Björk
Vice President Production at Genovis
Helsingborg, Skåne County, SE2 -
Rikke Rytter
VP Sales and Marketing at Genovis
Copenhagen, DK11 -
2
-
25
-
Maria Ekemohn
Senior Marketing and Communications Manager at Genovis
Kalmar County, Sweden2
Related Companies
